Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway

Endocrine-Related Cancer

Volumn 19, Issue 3, 2012, Pages 321-331

  Chen, Hongbing ^a,b   Sun, Yin ^b   Wu, Chengyu ^c   Magyar, Clara E ^b   Li, Xinmin ^b   Cheng, Liang ^d   Yao, Jorge L ^e   Shen, Steven ^f   Osunkoya, Adeboye O ^g   Liang, Chaozhao ^a   Huang, Jiaoti ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^f HOUSTON METHODIST HOSPITAL   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CHEMOKINE RECEPTOR CXCR2; GENOMIC DNA; INTERLEUKIN 8; PROTEIN P53; RNA; SMALL INTERFERING RNA;

ARTICLE; CANCER HORMONE THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; PATHOGENESIS; POLYMERASE CHAIN REACTION; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; PROSTATECTOMY; SMALL CELL CARCINOMA; SMALL CELL NEUROENDOCRINE CARCINOMA; TISSUE MICROARRAY; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-8; MALE; MUTATION; PROSTATIC NEOPLASMS; RECEPTORS, INTERLEUKIN-8B; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862650290     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0368     Document Type: Article

References (34)

1. Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da Costa M, Brown C, Popov N et al. 2008 Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133 1006-1018. (doi:10.1016/j.cell.2008.03.038)
2. Balk SP & Knudsen KE 2008 AR, the cell cycle, and prostate cancer. Nuclear Receptor Signaling 6 e001.
3. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ & Lucia MS 2003 Molecular characterization of human prostate carcinoma cell lines. Prostate 57 205-225. (doi:10.1002/pros. 10290)
4. Bonkhoff H 2001 Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Annals of Oncology 12 (Suppl 2) S141-S144. (doi:10.1093/annonc/12.suppl-2.S141)
5. Brown JR, Wieczorek TJ, Shaffer K & Salgia R 2003 Small-cell cancers, and an unusual reaction to chemotherapy. Case 1. Extrapulmonary small-cell carcinoma arising in the prostate. Journal of Clinical Oncology 21 2437-2438. (doi:10.1200/JCO.2003.081.03)
6. Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A, Hayek O, Dorai T & Buttyan R 1999 Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. Journal of Urology 162 1800-1805. (doi:10.1016/S0022-5347(05)68241-9)
7. Cooperberg MR, Park S & Carroll PR 2004 Prostate cancer 2004: insights from national disease registries. Oncology 18 1239-1247 (discussion 1248-1250, 1256-1258).
8. Erasmus CE, Verhagen WI, Wauters CA & van Lindert EJ 2002 Brain metastasis from prostate small cell carcinoma: not to be neglected. Canadian Journal of Neurological Sciences 29 375-377. (Pubitemid 35440091)
9. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ & Rosen JM 1995 Prostate cancer in a transgenic mouse. PNAS 92 3439-3443. (doi:10.1073/pnas.92.8.3439)
10. Grignon DJ 2004 Unusual subtypes of prostate cancer. Modern Pathology 17 316-327. (doi:10.1038/modpathol.3800052)
11. Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, Hicks JL, Eisenberger M, Nelson WG, Mostwin JL et al. 2009 Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 69 603-609. (doi:10.1002/pros.20910)
12. Huang J, Yao JL, Zhang L, Bourne PA, Quinn AM, di Sant'Agnese PA & Reeder JE 2005 Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. American Journal of Pathology 166 1807-1815. (doi:10.1016/S0002-9440(10)62490-X)
13. Huang J, Yao JL, di Sant'agnese PA, Yang Q, Bourne PA &Na Y 2006 Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate 66 1399-1406. (doi:10.1002/pros.20434)
14. Huang J, Wu C, di Sant'Agnese PA, Yao JL, Cheng L &Na Y 2007 Function and molecular mechanisms of neuroendocrine cells in prostate cancer. Analytical and Quantitative Cytology and Histology 29 128-138.
15. Isaacs WB, Carter BS & Ewing CM 1991 Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Research 51 4716-4720.
16. Kudahetti S, Fisher G, Ambroisine L, Foster C, Reuter V, Eastham J, Moller H, Kattan MW, Cooper CS, Scardino P et al. 2009 p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer. BJU International 104 20-24. (doi:10.1111/j.1464-410X.2009.08407.x)
17. Ma J, Ren Z, Ma Y, Xu L, Zhao Y, Zheng C, Fang Y, Xue T, Sun B & Xiao W 2009 Targeted knockdown of EGR-1 inhibits IL-8 production and IL-8-mediated invasion of prostate cancer cells through suppressing EGR-1/NF-kappaB synergy. Journal of Biological Chemistry 284 34600-34606. (doi:10.1074/jbc.M109.016246)
18. Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB &Matusik RJ 2001 A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Research 61 2239-2249. (Pubitemid 32692054)
19. Masumori N, Tsuchiya K, Tu WH, Lee C, Kasper S, Tsukamoto T, Shappell SB & Matusik RJ 2004 An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. Journal of Urology 171 439-442. (doi:10.1097/01.ju. 0000099826.63103.94)
20. Miyoshi Y, Uemura H, Kitami K, Satomi Y, Kubota Y &Hosaka M 2001 Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy. BJU International 88 982-983. (doi:10.1046/j.1464-4096.2001.00936.x)
21. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, Bushnell T, Huang L-S, Yang Q & Huang J 2009 Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate 69 787-798. (doi:10.1002/pros.20928)
22. Reiland J, Furcht LT & McCarthy JB 1999 CXC-chemokines stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptor. Prostate 41 78-88. (doi:10.1002/(SICI)1097-0045(19991001)41:2〈78::AID- PROS2〉3.0.CO;2-P)
23. Scher HI 2003 Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. Cancer 97 758-771. (doi:10.1002/cncr.11151)
24. Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M et al. 2008 Clinical significance of p53 alterations in surgically treated prostate cancers. Modern Pathology 21 1371-1378. (doi:10.1038/modpathol.2008.104)
25. Shen H, Schuster R, Lu B, Waltz SE & Lentsch AB 2006 Critical and opposing roles of the chemokine receptors CXCR2 and CXCR3 in prostate tumor growth. Prostate 66 1721-1728. (doi:10.1002/pros.20476)
26. Sun Y, Niu J & Huang J 2009 Neuroendocrine differentiation in prostate cancer. American Journal of Translational Research 1 148-162.
27. Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ &Huang J 2011 PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate 71 1668-1679. (doi:10.1002/pros.21383)
28. Tanaka M, Suzuki Y, Takaoka K, Suzuki N, Murakami S, Matsuzaki O & Shimazaki J 2001 Progression of prostate cancer to neuroendocrine cell tumor. International Journal of Urology 8 431-436 (discussion 437). (doi:10.1046/j.1442-2042.2001.00347.x)
29. Vashchenko N & Abrahamsson PA 2005 Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. European Urology 47 147-155. (doi:10.1016/j.eururo.2004.09.007)
30. Wang W & Epstein JI 2008 Small cell carcinoma of the prostate: a morphologic and immunohistochemical study of 95 cases. American Journal of Surgical Pathology 32 65-71. (doi:10.1097/PAS.0b013e318058a96b)
31. Wu C, Zhang L, Bourne PA, Reeder JE, di Sant'agnese PA, Yao JL, Na Y & Huang J 2006 Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer. Prostate 66 1125-1135. (doi:10.1002/pros.20412)
32. Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S, Liu Z, Tan D, Cheng L, Hatem F et al. 2006 Small cell carcinoma of the prostate: an immunohistochemical study. American Journal of Surgical Pathology 30 705-712. (doi:10.1097/00000478-200606000-00005)
33. Yuan TC, Veeramani S & Lin MF 2007 Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocrine-Related Cancer 14 531-547. (doi:10.1677/ERC-07-0061)
34. Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P & Nikitin AY 2006 Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Research 66 7889-7898. (doi:10.1158/0008-5472.CAN-06-0486)